Evaluating mismatch repair deficiency for solid tumor immunotherapy eligibility: immunohistochemistry versus microsatellite molecular testing
- 1 September 2021
- journal article
- research article
- Published by Elsevier in Human Pathology
- Vol. 115, 10-18
Abstract
No abstract availableKeywords
This publication has 47 references indexed in Scilit:
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockadeScience, 2017
- Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical OncologyJournal of Clinical Oncology, 2017
- PD-1 Blockade in Tumors with Mismatch-Repair DeficiencyNew England Journal of Medicine, 2015
- Immune Checkpoint Blockade: A Common Denominator Approach to Cancer TherapyCancer Cell, 2015
- MSIsensor: microsatellite instability detection using paired tumor-normal sequence dataBioinformatics, 2013
- Relevance, Pathogenesis, and Testing Algorithm for Mismatch Repair–Defective Colorectal CarcinomasThe Journal of Molecular Diagnostics, 2012
- A two-antibody mismatch repair protein immunohistochemistry screening approach for colorectal carcinomas, skin sebaceous tumors, and gynecologic tract carcinomasLaboratory Investigation, 2011
- Immunohistochemistry for PMS2 and MSH6 alone can replace a four antibody panel for mismatch repair deficiency screening in colorectal adenocarcinomaPathology, 2010
- Immunohistochemistry as First-line Screening for Detecting Colorectal Cancer Patients at Risk for Hereditary Nonpolyposis Colorectal Cancer SyndromeAmerican Journal of Surgical Pathology, 2009
- Cancer immunotherapy: The past, the present and the futureImmunology & Cell Biology, 2003